Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 25, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain a full financial performance report for the period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within employee benefit plans and trusts.
Material Changes
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan increased from 18,702,706 to 18,768,654 following fund movements on November 21, 2003. The average price was $47.09.
- Employee Share Option Plan: Abacus (GSK) Trustees Limited transferred 12,754 Ordinary shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991 on November 24, 2003.
Management Commentary and Risks
Management commentary is limited to the disclosure that Directors Dr. J.P. Garnier and Mr. J.D. Coombe are potentially interested in shares held within the discretionary funds and trusts mentioned above, in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding operations or financial outlook are disclosed in this filing.
Investor Verification Points
- Verify the total number of shares held by the US Retirement Savings Plan and the GSK Trust to assess potential voting power or dilution.
- Confirm the specific shareholding positions of Directors Dr. J.P. Garnier and Mr. J.D. Coombe outside of these discretionary funds.
- Note that this filing does not contain operational or financial results; refer to Form 20-F for comprehensive financial data.